OTOF and deafness: The first clinical trials of AAV-mediated gene therapy for DFNB9 human deafness, an autosomal recessive congenital form of deafness caused by pathogenic OTOF variants10, were recently conducted and yielded promising results supporting broader development of this approach11,12.